ÇмúÇà»ç

Korean Society of Gastrointestinal Cancer Research

Çмú´ëȸ ÀÚ·á½Ç

Á¦16ȸ ´ëÇѼÒÈ­±â¾Ï¿¬±¸ÇÐȸ Ãá°èÇмú´ëȸ

¼¼Á¾´ëÇб³ ÄÁº¥¼Ç¼¾ÅÍ ÄÁº¥¼ÇȦ 2021-06-11

Á¦16ȸ ´ëÇѼÒÈ­±â¾Ï¿¬±¸ÇÐȸ Ãá°èÇмú´ëȸ
ÄÁº¥¼Ç AȦ ÄÁº¥¼Ç BȦ
08:30-09:00 µî·Ï
09:00-09:10 Àλ縻 ÀüÈÆÀç ÀÌ»çÀå´Ô
09:10-10:20 Session I. ASCO/ESMO GI Cancer Symposium 2020 review (What is the NEW?) ÁÂÀå: Á¤Çö¿ë/¹æ½Â¹Î 09:10-10:20 Plenary session (Free paper presentation) ÁÂÀå: ¹Ú¼±ÀÚ/¹ÚÁ¤¿±
09:10-09:30 1. Upper GI tract °­¼±Çü(Ãæ³²´ë) 09:10-09:20 1. Anastomotic leakage and chronic presacral sinus after transanal total mesorectal excision (taTME) for rectal cancer: Comparative study to laparoscopic TME ¹®¼º¹Ì(°¡Å縯´ë)
09:20-09:30 2. A simple scoring model using endoscopic features for selection of colorectal cancer amenable to endoscopic resection À¯Á¾¿í(¿¬¼¼´ë)
09:30-09:50 2. Lower GI tract ±ÃÇöÁ¤(¼øõÇâ´ë) 09:30-09:40 3. Comparison of the microbiome diversity in gastric cancer patients and in Non-cancerous patients ¹æÀºÁÖ(°í·Á´ë)
09:40-09:50 4. Serial ctDNA monitoring in metastatic pancreatic cancer: A prospective clinical validation study Á¤±¤·Ï(¼­¿ï´ë)
09:50-10:10 3. Pancreatobiliary tract ÀüÁß¿ø(±¹¸³¾Ï¼¾ÅÍ) 09:50-10:00 5. Vimentin-positive circulating tumor cells as diagnostic and prognostic biomarkers in biliary tract cancer patients ÇѼº¿ë(ºÎ»ê´ë)
10:00-10:10 6. Programmed death-ligand 1 expression on tumor infiltrating immune cells is associated with better prognosis in biliary ±Ç¼ºÂù(¿¬¼¼´ë)
10:10-10:20 Q&A 10:10-10:20 7. Optimal adjuvant therapy in patients with borderline resectable and unresectable pancreatic cancer who had received neoadjuvant FOLFIRINOX ÃÖÁøÈ£(¼­¿ï´ë)
10:20-10:40 Coffee break
10:40-12:20 Session II. IASGO joint session : debate for challenging situations in GI malignancy ÁÂÀå: ÀüÈÆÀç/¹Ú¹«ÀÎ Session II. IASGO joint session: debate or controversial issues of PB malignancy ÁÂÀå: ¼Û½Ã¿µ/¿ì»ó¸í
10:40-11:00 1. Surgical roles for GE junction cancer: MIS with radicality and multimodality Ming Tsan Lin (National Taiwan University Hospital) 1. Neoadjuvant therapy in resectable and borderline resectable Á¶Àη¡(¼­¿ï´ë)
11:00-11:20 2. Periperatative chemotherapy for locally advaced GE junction cancer ±èÅÂÈ£(°¡Å縯´ë) 2. Upfront surgery in resectable (R) pancreatic cancer (PC), focusing on clinical benefits of neoadjuvant chemoradiotherapy versus up-front surgery for PC patients Shugo Mizuno (Mie University)
11:20-11:40 3. Radical surgery for rectal cancer after complete remission induced by CRT Soichiro Ishihara (The University of Tokyo Graduate School of Medicine) 3. Neoadjuvant chemotherapy vs. chemoradiotherapy in locally advanced pancreatic cancer: FOLFIRINOX Á¤¹®Àç(¿¬¼¼´ë)
11:40-12:00 4. Local excision or watch and wait for rectal cancer after CRT (or neoadjuvant therapy) with complete remission ±è¹ÎÁ¤ (¼­¿ï´ë) 4. Roles of conversion surgery for unresectable metastatic pancreatic cancer Masayuki Sho (Nara Medical University)
12:20-13:30 Luncheon symposium ÁÂÀå: ÀüÈÆÀç
12:20-13:00 The role of gemcitabine in pancreatie cancer ¹æ½Â¹Î(¿¬¼¼´ë)
13:00-13:30 ÃÑȸ
13:30-15:00 Session III. From bench to clinic, emerging issues on gastrointestinal cancer ÁÂÀå: ÃÖÈ£¼ø/ÁøÀ±Å 13:30-15:00 Session III. Appilcation of AI and big data in gastrointestinal cancers ÁÂÀå : ·ùÁö°ï/ÀÓÀ±Á¤
13:30-13:50 1. Present and future of Microbiome in GI cancers ¹ÚÇѼö(±¤ÁÖ°ú±â¿ø) 13:30-13:50 1. Big data analysis with the national health information database ±è¼ö¿µ(¿¬¼¼´ë ¿øÁÖ)
13:50-14:10 2. Application of the organoid in GI cancers ±¸ÀÚ·Ï(¼­¿ï´ë) 13:50-14:10 2. Cancer research using National Health Insurance big data ¹Úº´±Ô(±¹¹Î°Ç°­º¸ÇèÀϻ꺴¿ø)
14:10-14:30 3. Circulating tumor DNA as Biomarkers in GI cancer ±èµ¿¿í(ºÎ»ê´ë) 14:10-14:30 3. Image analysis with artificial intelligence in gastric cancer ¹æâ¼®(ÇѸ²´ë)
14:30-14:50 4. Single-cell analysis: New armamentarium for translational GI cancer research ÀÌÇý¿Á(Ä«Å縯´ë) 14:30-14:50 4. How to approach artificial intelligence: Guided by AI expert ±è±¤±â(°¡Ãµ´ë)
14:50-15:00 Q&A 14:50-15:00 Q&A
15:00-15:20 Coffee break
15:20-17:10 Session IV. Immunotherapy and target therapy of gastrointestinal cancers ÁÂÀå: ±èÈ£°¢/ȲÁøÇõ 15:20-17:10
16:00-16:50
Free paper session I
Free paper session II
ÁÂÀå:±èÇö¼ö/ÀÌ»óÇù
ÁÂÀå:±èº´Ã¢/ÇÑÁ¤È£
15:20-15:40 1. Introduction of immunotherapy and experience in other malignancy ±¸µ¿È¸(¼º±Õ°ü´ë) 15:20-15:28 S-1. Impact of gross tumor morphology on the clinical outcomes of Non-metastatic colon cancer: Multicenter retrospective cohort study ÇѼÒÁ¤(¿¬¼¼´ë)
15:28-15:36 S-2. BRCA 1/2 mutation predicts the treatment response of FOLFIRINOX in patients with pancreatic ductal adenocarcinoma ¹ÚÁöÈÆ(¿¬¼¼´ë)
15:36-15:44 S-3. Prognostic significance of lymph node status in resected ampullary adenocarcinoma followed by adjuvant chemotherapy ¹Ú³²¿µ(¼­¿ï´ë)
15:40-16:00 2. Prospects for immunotherapy and targeted therapy in gastric cancer ¹®Èñ¼®(Ãæ³²´ë) 15:44-15:52 S-4. M-RNA expression of signet ring cell carcinoma is different from that of poorly cohesive carcinoma in early gastric cancer °­¼±Çü(Ãæ³²´ë)
15:52-16:00 S-5. Serum biomarker panels for the detection of pancreatic cancer ½Åµ¿¿ì(¼­¿ï´ë)
16:00-16:20 3. Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy ±èÀº¼±(°í·Á´ë) 16:00-16:08 S-6. Development of a cachexia-diagnostic model using trajectories of skeletal muscle change ±è½Ã¿µ(¿¬¼¼´ë)
16:08-16:16 S-7. Predicting pulmonary thromboembolism in patients with gastrointestinal cancer using XGBoost machine learning model ±èÁÖ¼º(¼­¿ï´ë)
16:16-16:24 S-8. A new approaching technique of fluoroscopic-guided biliary biopsy for bile duct stenosis with loop tip guidewire ÀÌ°­¿ø(°í·Á´ë)
16:20-16:40 4. Promising immunotherapy and targeted therapy in pancreatobilary cancer ¹ÚÁÖ°æ(¼º±Õ°ü´ë) 16:24-16:32 S-9. Effect of fruit and vegetable intake on the risk of esophageal cancer in a large cohort ¹ÚÁ¤È£(°æºÏ´ë)
16:32-16:40 S-10. Long term safety and efficacy of etomidate in comparison with propofol as sedative in gastric neoplasm for endoscopic submucosal dissection ÀüÇÑÁ¶(°í·Á´ë)
16:40-16:50 Q&A 16:40-16:50 Q&A
16:50-17:10 Best presentation award
17:10- Adjourn